##  [Environmental Risk Assessment (ERA) Services](/chemicals/environmental-risk-assessment-era-services) 

![Cosmetic Product Labeling Review]()  


# Environmental Risk Assessment (ERA) Services

Protect ecosystems • Secure MAAs • Comply with EMA 2024 ERA guideline

[Get Started!](javascript:void(0))







- [Overview](#overview)
- [Testimonials](#testimonial)
- [Insights](#insights)







## What is ERA?

An [Environmental Risk Assessment (ERA)](https://www.freyrsolutions.com/blog/eras-for-pharmaceuticals-in-the-eu-major-regulatory-updates-and-requirements) is the structured process of assessing potential harm to the environment from a chemical substance, or active pharmaceutical ingredient (API). For chemicals and pharmaceuticals, the ERA report is prepared based on the intended use of the product and the physico-chemical, ecotoxicological, and environmental-fate properties of its active substance(s). The assessment translates laboratory and monitoring data into practical conclusions about environmental exposure and hazard.



![]()







## Why ERA matters

The EMA compliance now requires an [Environmental Risk Assessment](https://www.freyrsolutions.com/infographics/environmental-risk-assessments-for-pharmaceuticals-eu-regulatory-landscape-regulatory-framework) for marketing authorisation applications (MAAs) for human medicinal products — ERA findings inform labelling, Environmental hazard and risk mitigation and Module 1.6 of the eCTD dossier. Freyr helps you translate regulatory requirements into a robust, defensible ERA so your submission meets authority expectations while protecting aquatic and terrestrial ecosystems.



![]()







#### Click here to view the   
Regulatory frameworks of ERA for Human Pharmaceuticals for Different Markets

[Click Here](javascript:void(0))







## Our ERA Services

Freyr provides pragmatic, regulatory-aligned ERA Compliance support for Environmental Risk Assessments (ERA) through the following specialized ERA Consulting services:

![ESG Reporting Solutions]()

Comprehensive Data Gap Analysis

Scientific literature review and data gap analysis

[Explore Insights](javascript:void(0))





![ESG Reporting Solutions]()

ERA Report Preparation (CTD Module 1.6)

Prepare an ERA report (for active substance and major metabolite) as part of CTD Module 1.6 of a MAA

[Request Report](javascript:void(0))





![ESG Reporting Solutions]()

PBT Assessment /vPvB Risk Assessment

PBT (Persistent, Bioaccumulative and Toxic)/vPvB (very Persistent and very Bioaccumulative) Assessment

[Assess Risks](javascript:void(0))





![ESG Reporting Solutions]()

Tailored Testing & Assessment Strategy

Tailored testing or specific assessment strategy for antibiotic, antiparasitic active substances or endocrine active substances (EASs)

[Get Strategy ](javascript:void(0))





![ESG Reporting Solutions]()

Data Waiver Justification Support

Preparation of data waivers to reduce testing

[Reduce Testing- ](javascript:void(0))





![ESG Reporting Solutions]()

Study Summaries & Documentation

Robust study summaries preparation for physico-chemical, environmental fate and ecotoxicological effect studies

[View Summary](javascript:void(0))





![ESG Reporting Solutions]()

Laboratory Testing Support

Assist in conducting Lab Test to fill the data gap

[Initiate Testing](javascript:void(0))











## Frequently Asked Questions (FAQs) on Environmental Risk Assessment (ERA)

We are here to provide you with the information you need quickly and efficiently.



### 01. What is an Environmental Risk Assessment (ERA)?

An ERA evaluates the potential environmental impact of medicinal or chemical products, assessing their effects on water, soil, air, and organisms after use or disposal.





### 02. Why is an ERA required for pharmaceuticals?

As per EU Directive 2001/83/EC and EMA’s 2024 guideline, an ERA is mandatory for new MAAs to ensure that human medicines do not cause unacceptable environmental risks.





### 03. At what stage is an ERA submitted?

ERA is included in Module 1.6 of the eCTD dossier for new MAAs and must be updated for variations or extensions that increase environmental exposure.





### 04. What substances are covered under ERA?

All pharmacologically active substances in a medicinal product require ERA evaluation, while excipients are generally exempted.





### 05. What are the main phases of an ERA?

ERA has two phases:

- Phase I – Screens potential environmental risk.
- Phase II – Conducts detailed fate, persistence, and ecotoxicity studies if risk is indicated.





### 06. What is a vPvB/PBT assessment?

It assesses if a substance is Persistent, Bioaccumulative, and Toxic (PBT) or very Persistent and very Bioaccumulative (vPvB), indicating long-term environmental risks.





### 07. Are ERAs required for generic medicines?

Yes. Generic MAAs must include an ERA unless valid ERA data from the reference product remain applicable and scientifically justified.





### 08. Can previously submitted ERA data be reused?

Yes, if data sharing agreements exist or applicants can justify that previous ERA conclusions remain valid under the 2024 EMA guideline.





### 09. What happens if an active substance poses a risk to the environment?

Risk mitigation measures are required, such as disposal instructions, environmental warnings in product labeling, or restrictions on product use.





### 10. How does Freyr support ERA compliance?

Freyr offers end-to-end ERA support—data gap analysis, PBT/vPvB assessments, CTD-ready summaries, tailored strategies for specific substances, and expert regulatory guidance.





### 11. What are the key guidelines referenced for ERA?

- EMA Guideline on ERA of Medicinal Products for Human Use (2024)
- REACH Regulation Annex XIII
- OECD Test Guidelines for fate and ecotoxicity.





### 12. What are the consequences of non-compliance with ERA requirements?

Incomplete ERA documentation can delay or jeopardize marketing authorization and lead to regulatory queries or requests for additional data.
















.sustainability-compliance .grid { display: flex; gap: 20px; flex-wrap: wrap; justify-content: center; justify-items: center; }
.sustainability-compliance .card { height: 385px; width: 360px; }